Trump Orders 100 % Tariff Threat on Patented Drug Imports and Resets Metal Duties

Washington’s turn toward punitive pharma tariffs echoes Richard Nixon’s 10 % across-the-board surcharge in 1971 and, further back, the Smoot-Hawley duties of 1930—both framed as emergency maneuvers to protect U.S. industry yet ultimately spurring retaliation and supply-chain shifts. Trump’s latest move, pivoting from the global “Liberation Day” tariffs struck down by the Supreme Court in February, exemplifies a longer arc in which presidents stretch national-security statutes (from Eisenhower’s 1958 oil quotas to Trump’s 2018 steel tariffs) to manage economic policy unilaterally. By singling out patented drugs—an industry that once seemed tariff-proof—Washington signals that the same de-risking logic applied to semiconductors now extends to health-care supply chains. Whether this cements a 21st-century mercantilist regime or fades like past surcharges will shape manufacturing geography, R&D incentives, and allied trade relations for decades; on a century scale, it marks another ratchet in the steady politicization of global commerce rather than an isolated outburst.